Navigation Links
Smoking negatively affects response to anti-TNF treatment in patients with rheumatoid arthritis
Date:6/8/2012

Berlin, Germany, June 8 2012: A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, reinforces current thinking that smoking negatively affects treatment response in rheumatoid arthritis (RA) patients treated with anti-tumour necrosis factor (anti-TNF) drugs.

This American study, the largest of its kind, followed 2,811 treatment nave patients initiated onto anti-TNF therapy. Of the study group, 19% (n=521) were smokers and 81% (n=2,290) were non-smokers. Smokers had significantly higher scores on the Clinical Disease Activity Index (CDAI)* and DAS28** at six months than non-smokers. There was no significant difference in the odds of smokers versus non-smokers in achieving at least moderate EULAR*** response at six months and no difference in the change of mHAQ****.

Professor Ozlem Pala from the University of Miami Miller School of Medicine, USA and lead author of the study said: "There have been several studies which have investigated factors affecting response to anti-TNFs, but this is the first study to investigate response factors in such a large cohort of people. Being able to better predict response rates to treatment means that rheumatologists can discuss the findings with their patients who smoke and strongly encourage them to quit. This may also motivate them to develop successful strategies for smoking cessation in order to maximize effect of this expensive group of medications and potentially increase quality of life for these patients."

Disease activity measures at baseline were similar for DAS28 (approximately 3.7, standard deviation [SD]: 1.6) for both groups but higher for CDAI (17.1, SD: 13.8 vs 15.5, SD: 12.9) and mHAQ (0.5, SD: 0.5 vs 0.4, SD: 0.4) in smokers and non-smokers, respectively.

Patients were taken from the Consortium of Rheumatology Researchers of North America (CORRONA) registry. Mean duration of follow-up per patient was 3.4 years (SD: 2.6). Patients enrolled in the study were followed for up to 10.2 years. Biologic nave patients were followed for six months after initiation of an anti-TNF and outcomes of interest included DAS28, CDAI, mHAQ and EULAR response criteria after six months on therapy.


'/>"/>

Contact: Candice Debleu
eularpressoffice@cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Anti-tobacco TV ads help adults stop smoking, study finds
2. Exercise helps smokers to quit smoking, to remain smoke-free and to reduce the risk of death
3. Small neural focus groups predict anti-smoking ad success
4. Some women may be genetically predisposed to smoking-related hot flashes
5. Friends Parents Can Sway Teens Odds for Drinking, Smoking
6. Fewer Young Americans Smoking, Survey Finds
7. Vitamin C improves pulmonary function in newborns of pregnant smoking women
8. Genetic marker may predict smoking quantity in African Americans
9. 5 percent of workers gave up smoking when the anti-tobacco law took effect
10. Vitamin C improves lung function in newborns of pregnant smoking women
11. States Use Only Fraction of Tobacco Revenues to Fight Smoking, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... Opelousas, LA (PRWEB) , ... July 23, 2017 ... ... providers to interact, thus improving communication, safety and patient-provider relationships. New tools are ... according to results of the 19th Annual Health Care’s Most Wired® survey, released ...
(Date:7/23/2017)... ... July 23, 2017 , ... ... Florida Pain Relief Group – Melbourne, a practice owned by Physician Partners of ... interventional pain management, Dr. Stern also is certified in pediatrics, emergency medicine and ...
(Date:7/23/2017)... ... ... Viora Ltd., a leading medical aesthetics solutions manufacturer, is ... United States Patent and Trademark Office. The patent applies to treatments with Viora’s ... mechanisms to further increase the efficacy and safety of final treatment results for ...
(Date:7/22/2017)... , ... July 22, 2017 , ... ... year with the majority of patients not requiring pain medication after three months ... Sports Medicine’s Annual Meeting today in Toronto, Ontario, Canada found that those ...
(Date:7/21/2017)... PITTSBURGH, PA (PRWEB) , ... July 21, 2017 , ... ... I use a lot of pleural catheters available on the market," said an inventor ... level of comfort and safety for the patient." , He developed the patent-pending PLEURAL ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017  The global market for ... of approximately $394.1 million in 2016.  Although in early ... solid growth, in particular as a result of the ... and the recent introduction of a significant number of ... less-invasive testing of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a ... who suffer from painful intercourse and other painful pelvic pain conditions such ... to menopause. ... LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment and ... 2021, according to Medical Equipment & Supplies: ... Freedonia Focus Reports. Continued increases in demand for medical ... of the population and supported by gains in disposable ... and supplies. New product introductions will also drive sales ...
Breaking Medicine Technology: